HOME >> MEDICINE >> NEWS
UW-Madison Center One Of Two Sites Nationwide Selected For Clinical Trial Of Cancer Drug

MADISON - The University of Wisconsin Comprehensive Cancer Center has been chosen as one of two sites in the nation to conduct human tests of endostatin, a promising potential cancer treatment that seems to work in part by disrupting the growth of blood vessels that nourish tumor cells.

The National Cancer Institute (NCI) notified the UWCCC early this afternoon of its participation.

"We are honored and very excited to be taking part in these trials," said UWCCC Director Dr. John Niederhuber. "This is an important opportunity to answer some key questions about a very interesting compound."

Endostatin's potential value as a cancer treatment received worldwide attention after a May 1998 New York Times article described early results in mice in the laboratory of Dr. Judah Folkman of Harvard Medical School. In May 1998, the NCI called animal studies on the compound "encouraging" and later announced it would entertain applications from research organizations to conduct tests in humans.

In animal studies, endostatin inhibited the growth of already existing tumors and caused some to shrink to microscopic lesions. When researchers examined those tiny lesions, they found the endostatin had blocked the growth of blood vessels that nourished the tumors.

Researchers also conducted tests in which mice were given endostatin until their tumors shrank, at which time the treatment was stopped. Treatment resumed when the tumors began to grow back. In each case, the tumors in mice became smaller when endostatin was given. Significantly, the tumors did not develop resistance to endostatin even after six cycles of treatment.

The trials at UW will be "Phase 1" tests in which researchers will try to discover the maximum dose patients can tolerate without undue toxicity. Initially, three to six patients will receive small doses of the drug and will be carefully monitored for toxic effects. Additional patients will then receive graduated doses of the drug. Al
'"/>

Contact: Lisa Brunette
labrunet@facstaff.wisc.edu
608-263-5830
University of Wisconsin-Madison
19-Mar-1999


Page: 1 2

Related medicine news :

1. UW-Madison receives $10 million for cancer communications research
2. UW-Madison leads $26 million study on aging
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. UCLA Medical Center becomes first hospital to introduce remote presence robots in ICU
5. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
6. Surgeon General at Childrens Hospital & Research Center at Oakland
7. Yale opens Center for Interdisciplinary Research on AIDS (CIRA) in India
8. Olson family donates $1 million to Arizona Cancer Center
9. Entrepreneurism Center at UC San Diego funds commercialization of lung, shock, other devices
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Harlem Hospital Center, Columbia affiliate, recognized for efforts to fight glaucoma

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... August 31, 2020 , ... Bonde Innovations, LLC, a venture-backed ... heart failure, today announced that the company has been awarded a Phase 1 ... National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). ...
(Date:8/28/2020)... ... August 28, 2020 , ... WHAT , Hespiro™ is ... with respiratory conditions, including COVID-19, while reducing the need for scarce mechanical ventilators. ... exhaled gas and scrubs it free of carbon dioxide in a completely closed ...
(Date:8/28/2020)... ... ... Integrated Viral Protection (IVP Air) today announced that the True North Classical ... Indoor Air Protection System that is the first system designed and proven to catch ... the filtration system on September 8th. , The IVP Air S1 model is ...
(Date:8/27/2020)... ... 2020 , ... Walk-in Dermatology’s SK-IN Medical Aesthetics Center announced ... York location. , Loren received her New York esthetic license in 2009 ... peels, microdermabrasion, Hydrafacial MD, dermaplaning, facial lymphatic, and various laser procedures. Loren is ...
(Date:8/26/2020)... ... 2020 , ... Smile Brands Inc. CEO, Steven C. Bilt, ... a session entitled, “A CEO Guide for Delivering and Measuring Inclusion Success”. The ... together the world’s leading diversity and inclusion executives, HR consultants, and D&I activists ...
Breaking Medicine News(10 mins):
(Date:8/26/2020)... ... August 26, 2020 , ... Hero Life Sciences announced today that ... 3 ply surgical disposable face masks and N95 respirators in its manufacturing plant located ... challenge that most Americans are facing in trying to find quality disposable face masks ...
(Date:8/26/2020)... ... 26, 2020 , ... NucleusHealth, LLC, a provider of market ... and Chief Executive Officer effective immediately. Dr. Vishal Verma, the previous CEO, will ... , Mr. Hooton, a seasoned business executive, joined the company in February ...
(Date:8/26/2020)... SAN DIEGO (PRWEB) , ... August 25, 2020 ... ... opening of its brand new Stem Cell Treatment Center to give ... stress free environment. With this announcement, ProgenCell establishes its leadership in the field ...
Breaking Medicine Technology:
Cached News: